Printer Friendly

BAKER NORTON PHARMACEUTICALS RECEIVES LICENSE FROM BOSTON UNIVERSITY FOR METHOD TO TREAT CERTAIN INVOLUNTARY MOVEMENT DISORDERS

 MIAMI, Feb. 25 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) and Boston University announced today that Boston University granted IVAX' wholly owned subsidiary, Baker Norton Pharmaceuticals, Inc., a worldwide license to the use of opiate antagonists, such as nalmefene, to treat involuntary movement disorders, including tardive dyskinesia and Huntington's disease.
 Tardive dyskinesia is a disorder characterized by involuntary movements. It may be caused by long term administration of anti- psychotic or neuroleptic drugs, such as haloperidol. Huntington's Disease is an involuntary movement disorder of genetic origin. In a pilot clinical trial in Huntington's Disease patients conducted by investigators at Boston University Medical Center, opiate antagonists have been shown to decrease some of these involuntary movements.
 Neuroleptic drugs are commonly used in older patients including those suffering from Alzheimer's Disease to control behavior. Evidence suggests that tardive dyskinesia prevalence rates may be as high as 36 percent in persons treated with neuroleptic medications. The administration of nalmefene may prevent the development of tardive dyskinesia as a side effect of anti-psychotic or neuroleptic medications. Baker Norton Pharmaceuticals intends to conduct clinical studies to evaluate the efficacy of nalmefene in combination with neuroleptics in tardive dyskinesia patients and will be responsible for obtaining the required regulatory approvals.
 Nalmefene is being developed by Baker Norton Pharmaceuticals for a number of indications, including as an orally administered drug for the treatment of interstitial cystitis and as an injectable drug for the treatment of central nervous system injuries. In addition, Baker Norton Pharmaceuticals has granted to Anaquest, Inc. an exclusive license in the United States, Canada and Western Europe to the injectable form of nalmefene for the reversal of benzodiazepine induced hypotension and for the reversal of the effects of narcotic anesthesia and narcotic overdoses.
 Dr. Phillip Frost, chairman of IVAX Corporation, said "The use of nalmefene for this new application will complement Baker Norton's program for the development of central nervous system drugs. The preliminary data obtained by Boston University Medical Center for this indication is encouraging. If successful, administration of nalmefene in conjunction with neuroleptic drugs will allow for a more effective and expanded use of neuroleptics by patients requiring such therapy."
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Norton Pharmaceuticals, Inc., a manufacturer, developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of generic pharmaceuticals in the United Kingdom, Ireland and other countries; H.N. Norton Co. (formerly LuChem Pharmaceuticals, Inc.), a manufacturer of generic pharmaceuticals in the United States; Goldline Laboratories, Inc., a national marketer of generic prescription and over-the-counter pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Flori Roberts, Inc., a skin care and cosmetics company; DVM Pharmaceuticals Inc., a veterinary products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l, a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 2/25/93
 /CONTACT: Richard C. Pfenniger Jr. , senior vice president-legal affairs of IVAX Corporation, 305-590-2309/
 (IVX)


CO: IVAX Corporation; Baker Norton Pharmaceuticals; Boston University ST: Florida, Massachusetts IN: MTC SU:

JJ-JB -- FL001 -- 0229 02/25/93 08:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1993
Words:536
Previous Article:DEFENSE TECHNOLOGY EXPO DRAWS MORE THAN 1,400 ON FIRST DAY
Next Article:SEMINOLE COUNTY: CENTRAL FLORIDA'S BEST VALUE
Topics:


Related Articles
IVAX CORPORATION ANNOUNCES THE ACQUISITION OF THREE BRAND NAME PHARMACEUTICAL PRODUCTS
BAKER CUMMINS PHARMACEUTICALS RECEIVES LICENSE TO CHEMOPROTECTIVE DRUG
IVAX' SUBSIDIARY RECEIVES APPROVAL TO SELL SODIUM CROMOGLYCATE METERED DOSE INHALER IN THE UNITED KINGDOM
IVAX ANNOUNCES JOINT DEVELOPMENT AGREEMENT WITH GLAXO
BAKER CUMMINS PHARMACEUTICALS CHANGES ITS NAME TO BAKER NORTON PHARMACEUTICALS
BAKER NORTON PHARMACEUTICALS RECEIVES LICENSE FROM RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT BUFFALO FOR NEW VASODILATOR THERAPY
IVAX ANNOUNCES THE APPROVAL OF ELMIRON(R) IN CANADA
FDA Responds to IVAX's Paxene(R) Application
IVAX Receives Its First Patent For Orally-Administered Paclitaxel.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters